Our Mission
Our goal is to develop collaborative, impactful research that will lead to improved brain health for the people of Cleveland, and for all.
NervGen celebrates successful Phase1b/2a trial
NervGen, founded by the late Jerry Silver, recently completed a clinical trial on their novel compound NVG-291 for the pharmacologic treatment of chronic spinal cord injury. The results showed lasting improvement in limb and bladder function and quality of life in patients treated with the novel compound.
The Latest
We hope to see you at the launch of the new Cleveland Neuro Collective on August 25th, 2026. Hear speakers Dr. Andrew Pieper and Dr. Marissa Scavuzzo discuss their innovative research that has applications in treating a variety of diseases including: Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, and more.